When building your watch list, look for stocks with an 80 or higher RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
History shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Keros Therapeutics Stock A Buy?
Keros Therapeutics stock reclaimed its 200-day moving average on Wednesday and is not currently near a potential buy zone. See if the biotech stock goes on to build a promising consolidation that could kick off a new price move.
The biotech company showed 0% earnings growth in its most recent report. Sales rose -100%.
Keros Therapeutics stock holds the No. 154 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
